Continuous Glucose Monitor (CGM) Use in COVID-19 Patients
Overview
Tab Title Description
Study type
InterventionalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Jacksonville, Florida: 20-010816
NCT ID: NCT04756141
About this study
The purpose of this research is to determine if CGM (continuous glucose monitors) used in the hospital in patients with COVID-19 and diabetes treated with insulin will be as accurate as POC (point of care) glucose monitors. Also if found to be accurate, CGM reading data will be used together with POC glucometers to dose insulin therapy.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Patients 18 years or older.
- Patients with diagnosis of COVID-19 respiratory infection.
- Patient with recent positive SARS-COV2 infection and still positive PCR admitted of non-respiratory diagnoses.
- Diagnosis of diabetes mellitus type 1 or type 2.
- Diagnosis of medication (steroid) induced hyperglycemia (persistent glucose more than 180 mg/dl).
- Taking insulin either SQ or IV.
Exclusion Criteria:
- Patient in shock.
- Patient intubated on mechanical ventilation.
- Patient placed on ECMO.
- Patient taking hydroxyurea.
- Patient taking more than 4g of acetaminophen in 24 hours or more than 1g acetaminophen in 6 hours.
- Pregnant or nursing female patients.
- Patients with skin lesions at the application site that may interfere with placement of the sensor.
- Patients with known allergy to medical grade adhesive.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Jacksonville, Fla.
Mayo Clinic principal investigator Adrian Dumitrascu, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available